西尔德纳菲尔改善了缩性心力衰竭患者的运动血液动力学和氧气吸收
Gregory D Lewis1, Justine Lachmann, Janice Camuso
1Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Circulation
|December 21, 2006
概括
席尔德纳菲尔通过选择性扩张肺动脉,改善了心力衰竭患者的运动能力和血液动力学. 这种治疗增强了氧气吸收,并减少了呼吸效率低下.
科学领域:
- 心血管医学 心血管医学
- 肺高血压研究 肺高血压研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 通常涉及到肺血管中的氧化信号受损.
- 西尔德纳菲尔是一种固酶5型抑制剂,增强周期性GMP水平,降低肺血管抵抗力.
- 该研究研究了西尔代纳菲尔对炼能力和血动力学在缩性高血压中所产生的影响.
研究的目的:
- 评估单次口服西尔代纳菲尔 (50毫克) 剂量对慢性静心性心力衰竭患者的运动能力和血液动力学的影响.
- 为了确定西尔代纳菲尔诱导的肺血管扩张是否能改善运动表现.
- 评估西尔德纳菲尔在休息和运动期间对肺血管抵抗的选择性影响.
主要方法:
- 十三名患有NYHA III类高血压的患者接受了50毫克口服西尔代纳菲尔.
- 右心脏血液动力学,气体交换和放射性核酸室内扫描被评估在休息和运动期间,在西尔德纳菲尔前后.
- 分析的重点是肺动脉压的变化,血管阻力,心脏指数和运动参数,如VO2峰值和VE/VCO2斜率.
主要成果:
- 西尔德纳菲尔显著降低了静止肺动脉压,全身血管阻力和肺血管阻力,同时增加了心脏指数.
- 在运动期间,西尔德纳菲尔降低了肺动脉压和肺血管阻力,表明选择性肺血管扩张.
- 峰值VO2增加了15%,VE/VCO2斜率降低了16%,主要在患有二次性肺高血压的患者中观察到改善.
结论:
- 西尔德纳菲尔 (50毫克) 改善运动能力 (峰值VO2) 和减少呼吸系统低效率 (VE/VCO2斜率) 在心筋急性肺高血压的心肺高血压患者.
- 药物作为选择性肺血管扩张剂在休息和运动期间在这个患者群体.
- 用西尔德纳菲尔抑制固酶5型可为患有肺高血压的高血压患者提供治疗效益.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Heart Failure Drugs: β-Blockers
3.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
3.0K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
842
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
842
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
826
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
826
Heart Failure V: Medical Management
642
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
642
Heart Failure VI: Adjunct Therapies
635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635


